[1] Bonfield TL, Nolan Koloze MT, Lennon DP,et al. Defining human mesenchymal stem cell efficacy in vivo. J Inflamm (Lond). 2010 ;7:51.
[2] Moulton VR, Tsokos GC. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther. 2011;13(2): 207.
[3] Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-939.
[4] Hutloff A, Dittrich AM, Beier KC,et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;397(6716):263-266.
[5] Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010;22(3):326-332.
[6] Odegard JM, DiPlacido LD, Greenwald L,et al. ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus. J Immunol. 2009;182(7):4076-4084.
[7] Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol. 2008;20(5):519-525.
[8] Wong CK, Lit LC, Tam LS,et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008;127(3):385-393.
[9] Henriques A, Inês L, Pais ML,et al.Th17 cells in systemic lupus erythematosus share functional features with Th17 cells from normal bone marrow and peripheral tissues. Clin Rheumatol. 2012 ;31(3):483-491.
[10] Breitfeld D, Ohl L, Kremmer E,et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000; 192(11):1545-1552.
[11] Dong W, Zhu P, Wang Y,et al. Follicular helper T cells in systemic lupus erythematosus: a potential therapeutic target. Autoimmun Rev. 2011;10(6):299-304.
[12] Craft JE. Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol. 2012 ;8(6):337-347.
[13] Simpson N, Gatenby PA, Wilson A,et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 2010;62(1):234-244.
[14] Pierangeli SS, Chen PP, Raschi E,et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost. 2008 ;34(3):236-250.
[15] Pierangeli SS, Chen PP, González EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol. 2006;13(5):366-375.
[16] Mackay F, Figgett WA, Saulep D,et al. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev. 2010;237(1): 205-225.
[17] Davidson A.The rationale for BAFF inhibition in systemic lupus erythematosus. Curr Rheumatol Rep. 2012;14(4):295- 302.
[18] Ota M, Duong BH, Torkamani A,et al. Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol. 2010;185(7):4128-4136.
[19] Shirota Y, Yarboro C, Fischer R,et al. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118-128.
[20] Kyttaris VC, Tsokos GC.Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. Curr Opin Rheumatol. 2011;23(5):449-453.
[21] Chung SW, Park JW, Lee SA,et al. Thrombin promotes proinflammatory phenotype in human vascular smooth muscle cell. Biochem Biophys Res Commun. 2010;396(3): 748-754.
[22] Yuan W, DiMartino SJ, Redecha PB,et al. Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the presence of immune complexes. Arthritis Rheum. 2011;63(1):212-218.
[23] Weckerle CE, Mangale D, Franek BS,et al. Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus. Arthritis Rheum. 2012;64(9):2947-2952.
[24] Shirinsky I, Polovnikova O, Kalinovskaya N,et al. The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study. Rheumatol Int. 2012. [Epub ahead of print]
[25] Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 2012;67(1): 1-8.
[26] 张培培,刘慧纯,王世民,等.脑缺血再灌注损伤大鼠尾静脉移植脐带间充质干细胞的安全性[J].中国组织工程研究,2012,16(14): 2581-2584.
[27] Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells. 2010; 28(3):585-596.
[28] Mariño E, Grey ST. B cells as effectors and regulators of autoimmunity. Autoimmunity. 2012;45(5):377-387.
[29] Traggiai E, Volpi S, Schena F,et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells. 2008; 26(2):562-569.
[30] Asari S, Itakura S, Ferreri K,et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol. 2009; 37(5):604-615.
[31] Schena F, Gambini C, Gregorio A,et al. Interferon-γ- dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum. 2010; 62(9):2776-2786.
[32] Asari S, Itakura S, Ferreri K,et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol. 2009; 37(5):604-615.
[33] Ma X, Che N, Gu Z,et al. Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation. Cell Transplant. 2012. [Epub ahead of print]
[34] Najar M, Raicevic G, Boufker HI,et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol. 2010;264(2):171-179.
[35] Yagi H, Soto-Gutierrez A, Parekkadan B,et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant. 2010;19(6):667-679.
[36] Fu QL, Chow YY, Sun SJ,et al. Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis. Allergy. 2012;67(10): 1215-1222.
[37] Sun YQ, Deng MX, He J,et al. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. Stem Cells. 2012;30(12):2692-2699.
[38] Hemeda H, Jakob M, Ludwig AK,et al. Interferon-gamma and tumor necrosis factor-alpha differentially affect cytokine expression and migration properties of mesenchymal stem cells. Stem Cells Dev. 2010;19(5):693-706.
[39] Yang SH, Park MJ, Yoon IH,et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med. 2009;41(5):315-324.
[40] Yagi H, Soto-Gutierrez A, Parekkadan B,et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant. 2010;19(6):667-679.
[41] English K.Mechanisms of mesenchymal stromal cell immunomodulation.Immunol Cell Biol. 2013;91(1):19-26.
[42] Duffy MM, Pindjakova J, Hanley SA,et al. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol. 2011;41(10):2840-2851.
[43] Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther. 2010;21(12):1641-1655.
[44] Sun L, Akiyama K, Zhang H,et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans.Stem Cells. 2009; 27(6):1421-1432.
[45] Choi H, Lee RH, Bazhanov N,et al. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood. 2011; 118(2):330-338.
[46] François M, Romieu-Mourez R, Li M,et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2012;20(1):187-195.
[47] Zhang QZ, Su WR, Shi SH,et al. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells. 2010;28(10):1856-1868.
[48] Ylöstalo JH, Bartosh TJ, Coble K,et al. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells. 2012;30(10):2283-2296. |